Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-interferon alfa-2b in Platinum Resistant Ovarian Cancer
NCT00085384Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2002
- Primary completion
- Nov 2005
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peginterferon alfa-2b in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Optimal Biologic Dose at 8 weeks and Tumor Response at 12 weeks. Started Jul 2002; status: terminated.
02
Drugs
peginterferon alfa-2b
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00085384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085384.